Insmed Inc. (INSM), a global biopharmaceutical company, expects its lead drug Arikayce will sustain robust double-digit revenue growth on a global scale throughout 2024.
Approved by the FDA in Sep.2018, Arikayce is an aminoglycoside antibacterial indicated for the treatment of Mycobacterium avium complex (MAC) lung disease in adults who have limited or no alternative treatment options.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com